SCHEMBL2619360

SCHEMBL2619360

CCN(CC)c1cccc(OCCn2ccc3ccc(C(=O)NO)cc3c2=O)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.43
LMNA P02545 2/20 0.40
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC6 Q9UBN7 8/20 0.40
HDAC3 O15379 5/20 0.40
HDAC1 Q13547 5/20 0.40
RAB9A P51151 1/20 0.39
HDAC8 Q9BY41 4/20 0.39
HDAC2 Q92769 3/20 0.39
HDAC10 Q969S8 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
HDAC4 P56524 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC5 Q9UQL6 2/20 0.39
NCOR2 Q9Y618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118644 0.84 HDAC6 (0.46) SMPD1MAPK1ALDH1A1HDAC6HDAC3
SCHEMBL4550110 0.84 SMPD1 (0.43) SMPD1HDAC6HDAC3HDAC1HDAC8
SCHEMBL4550059 0.83 MAPT (0.45) SMPD1LMNAALDH1A1MAPTHDAC6
SCHEMBL4550180 0.81 SMPD1 (0.56) SMPD1HDAC6HDAC3HDAC1HDAC8
SCHEMBL10268001 0.81 HDAC6 (0.51) MAPK1HDAC6HDAC3HDAC1HDAC8
SCHEMBL2116432 0.81 HDAC6 (0.56) SMPD1MAPK1ALDH1A1HDAC6HDAC3
SCHEMBL2619364 0.81 HDAC6 (0.46) LMNAMAPK1ALDH1A1MAPTHDAC6
SCHEMBL2619284 0.79 MAPT (0.43) SMPD1LMNAALDH1A1MAPTHDAC6
SCHEMBL2117041 0.79 HDAC6 (0.44) SMPD1HDAC6HDAC3HDAC1HDAC8
SCHEMBL4550034 0.79 HDAC6 (0.43) HDAC6HDAC3HDAC1HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 SMPD1 3414/4885LMNA 1584/4885MAPK1 2359/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 SMPD1 3414/4885LMNA 1584/4885MAPK1 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.